Results 11 to 20 of about 49,657 (223)

Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors.

open access: yesPLoS ONE, 2020
BackgroundChoice of initial antiretroviral therapy regimen may help children with HIV maintain optimal, continuous therapy. We assessed treatment-naïve children for differences in time to treatment disruption across randomly-assigned protease inhibitor ...
Dwight E Yin   +7 more
doaj   +1 more source

Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. [PDF]

open access: yes, 2020
IntroductionWeight gain following antiretroviral therapy (ART) initiation is common, potentially predisposing some persons with HIV (PWH) to cardio-metabolic disease.
Altoff, Keri N   +23 more
core   +1 more source

Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières [PDF]

open access: yes, 2008
OBJECTIVES: To describe the use of second-line protease-inhibitor regimens in Médecins Sans Frontières HIV programmes, and determine switch rates, clinical outcomes, and factors associated with survival.
Alexandra Calmy   +24 more
core   +2 more sources

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

open access: yes, 2022
Hepatology, EarlyView.
Robert J. Fontana   +6 more
wiley   +1 more source

Antiretroviral drug resistance mutations in naïve and experienced patients in Shiraz, Iran, 2014 [PDF]

open access: yes, 2016
Resistance to antiretroviral agents is a significant concern in the clinical management of HIV-infected individuals, particularly in areas of the world where treatment options are limited.
Aghasadeghi, M.R.   +6 more
core   +1 more source

Focus on chirality of HIV-​1 non-​nucleoside reverse transcriptase inhibitors [PDF]

open access: yes, 2016
Chiral HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) are of great interest since one enantiomer is often more potent than the corresponding counterpart against the HIV-1 wild type (WT) and the HIV-1 drug resistant mutant strains.
Famiglini, Valeria, Silvestri, Romano
core   +2 more sources

Antiretroviral treatment can affect the release of NO and EDCF, but EDH in rat arteries [PDF]

open access: yes, 2012
This journal suppl. entitled: EDHF 2012 - 10th Anniversary MeetingDespite improving clinical outcomes, highly active antiretroviral therapy (HAART) is an independent potential risk factor for cardiovascular diseases.
Lee, SS   +3 more
core   +1 more source

Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1 [PDF]

open access: yes, 2005
Increased susceptibility to the protease inhibitors saquinavir and amprenavir has been observed in human immunodeficiency virus type 1 (HIV-1) with specific mutations in protease (V82T and N88S).
Clotet, B   +7 more
core   +2 more sources

Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013–2016: Impact on susceptibility to first-line strategies including integrase strand-transfer inhibitors [PDF]

open access: yes, 2017
Objectives To characterize the prevalence of transmitted drug resistance mutations (TDRMs) by plasma analysis of 750 patients at the time of HIV diagnosis from January 1, 2013 to November 16, 2016 in the Veneto region (Italy), where all drugs included in
Alvarez, M   +18 more
core   +1 more source

Two-Drug Regimens for HIV—Current Evidence, Research Gaps and Future Challenges

open access: yesMicroorganisms, 2022
During the last 30 years, antiretroviral treatment (ART) for human immunodeficiency virus (HIV) infection has been continuously evolving. Since 1996, three-drug regimens (3DR) have been standard-of-care for HIV treatment and are based on a protease ...
Alexandre Pérez-González   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy